<DOC>
	<DOCNO>NCT01758744</DOCNO>
	<brief_summary>An Open Label , Pilot Study Testing Safety Efficacy Inhaled Treprostinil ( TyvasoÂ® ) Treatment Pulmonary Hypertension ( PH ) Associated Chronic Obstructive Pulmonary Disease ( COPD )</brief_summary>
	<brief_title>Treatment Pulmonary Hypertension Associated COPD With Inhaled Treprostinil-1</brief_title>
	<detailed_description>This pilot study 10 patient COPD-PH . Primary outcome measure see drug safe patient population secondary measure see drug improve patient functional capacity .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>must : age 30 80 clinical diagnosis Gold stage 2 4 COPD diagnosis pulmonary hypertension establish historic right heart catheterization minimum weight 45 Kg minimum systolic blood pressure &gt; 90 mmHg able perform six minute walk test able maintain oxygen saturation &gt; 88 % rest ( without oxygen ) treat background therapy COPD minimum 1 month prior consideration enrollment . competent understand information give Institutional Review Board ( IRB ) Independent Ethics Committee ( IEC ) approve Informed Consent Form must sign form prior initiation study procedure . Exclusion Criteria . Can : The presence pulmonary venous hypertension define historical right heart catheterization Gold Stage I COPD document leave ventricular dysfunction measure echocardiography pregnant breastfeeding Recipient lung transplant receive chronic prostanoid therapy pulmonary hypertension within 4 week prior screen appointment A requirement great 9 l/min O2 maintain oxygen saturation great 88 % rest No serious medical condition</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>COPD PH</keyword>
	<keyword>COPD associate Pulmonary Hypertension</keyword>
	<keyword>COPD Pulmonary Hypertension</keyword>
	<keyword>Disease</keyword>
</DOC>